Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Date:2/22/2010

> Subsequent Events

On February 15, 2010, the Company entered into an agreement with one of the holders of its convertible notes, Pope Investments LLC ("Pope"), whereby Pope agreed to waive certain provisions set forth in the November 2007 and May 2008 securities purchase agreements for the Company's debentures and convertible notes, provided that the Company has made the November 2009 interest payments to the holders of the Company's November 2007 debentures and May 2008 notes on or prior to February 25, 2010. If the interest payments are not made by February 25, 2010 all rights and remedies of Pope defined in the 2007 and 2008 Securities Purchase Agreements shall remain in full force and effect as if this waiver had not been granted.

The Company also agreed that in the event that its common stock has not been listed on the NASDAQ Stock Market on or prior to April 15, 2010, it will pay to the holders of the 2007 Notes and the 2008 Notes an amount equal to the difference between the interest on such Notes previously paid for the period from June 1, 2009 to November 30, 2009.


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... LAWRENCEVILLE, N.J. , March 5, 2015 /PRNewswire/ ... today that the Company will host a conference ... provide an update on its development programs for ... and two newly acquired technology platforms, TheraPlas™ and ... a.m. ET on Thursday, March 12, 2015. To ...
(Date:3/5/2015)... and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) has announced ... Accelerating growth to the next level - Moving up ... offering. Domestic sales improved in 2014, ... the market,s reaction to the new drug pricing policy. ... healthy, as the momentum continues and improving economic growth ...
(Date:3/5/2015)... HAMPTON, N.J. , March 5, 2015 /PRNewswire/ ... ), a leading global specialty biopharmaceutical company, and Ikaria, ... they have entered into a definitive agreement under which ... a Madison Dearborn -led investor group in a ... Subject to customary closing conditions, the parties expect the ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9
... 2, 2012  Trovagene, Inc. (Pink Sheets: TROV ... of a diagnostic test to determine the presence of ... specimens. The proprietary test (U.S. patent application pending) might, ... carrier status in males. The Company,s HPV ...
... Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical ... central nervous system disorders and pain, announced today that ... to the U.S. Food and Drug Administration (FDA) for ... candidate for the treatment of chronic pain.     ...
Cached Medicine Technology:Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine 2Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 Nutrition ... nutrition products, is pleased to offer reformulated Millennium 500 ... website, Millennium 500 is a German grade creatine supplement ... hydration, promote muscle recovery, and aid with overall strength ... compound that acts as a reserve energy source in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Wimbledon ... which provides vascular, echocardiogram and NCV testing, ... as the Chief Medical Officer. Dr. Artel will be ... development of the WimbledonMED program and the continued growth ... passionate about working with Wimbledon Health Partners as a ...
(Date:3/5/2015)... Colorful packaging and marketing promises make it ... health. But all it really takes is reading the ... the March 2015 Harvard Health Letter . , ... director of the Department of Nutrition at Harvard-affiliated Brigham ... all the markers of good nutrition. , Whole grains ...
(Date:3/5/2015)... Obesity can cause the human body ... one drinks each day can help promote weight loss ... water advocate Sharon Kleyne and sports doctor Robert Weil, ... Powers of Water® radio show. , Weil is ... orthotics and sports medicine. His weekly radio show, ...
(Date:3/5/2015)... Developers and plugin specialists of Final ... transition pack entitled TranSlice Wipe for FCPX. , “TranSlice ... ease while maintaining a professional look,” Said Christina Austin, ... time saver with transitions our users will love.” , ... screen transitions with a new style. TranSlice Wipe allows ...
Breaking Medicine News(10 mins):Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Tips to Find the Healthiest Breakfast Cereals, From the March 2015 Harvard Health Letter 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 3Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2
... plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the ... a 12-month study of DAYTRANATM (methylphenidate transdermal system), ... that DAYTRANA provided significant ADHD tolerability and symptom ... years. The study data was presented today ...
... Medically-complicated obesity is a societal problem that needs to ... is just one of the many complications of increased ... therefore there is an unmet need for pharmacologic treatment ... Journal of Gastroenterology by Dr. Baski-Bey et al. offers ...
... Calif., Oct. 26 Varian Medical,Systems, (NYSE: ... industry in overall,service performance by the ServiceTrak(TM) 2007 ... Ltd., a research company that,analyzes service trends in ... the basis of telephone interviews with,customers. Varian ...
... Highest Ranked Plan in Connecticut, FARMINGTON, Conn., Oct. ... plans by U.S. News & World Report/NCQA America,s Best,Health ... standards for,quality and customer satisfaction. ConnectiCare moved up one ... continues to be the highest ranked,plan in Connecticut. ...
... People with,diabetes who have asymptomatic heart disease may be ... hearts without surgical intervention, according,to a study being published ... on October 26, 2007., Researchers found that patients ... their cardiac risk factors with,medication were able to reverse ...
... Provide Funding and Support for "Patient Navigator,Program" Site ... Washington, EVERETT, Wash., Oct. 25 The ... Patient Navigator Program at,the Providence Regional Cancer Partnership ... part of a strategic nationwide effort to,significantly extend ...
Cached Medicine News:Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2Health News:Attenuation of NASH by stimulation of free fatty acid metabolism 2Health News:Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals 2Health News:ConnectiCare Ranked #5 Best Health Plan in America 2Health News:Aggressively Treating Cardiac Risk Factors May Reverse Ischemia 2Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 2Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 3Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4Health News:Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: